drugset / Trial / NCT06427668
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
Timeline
- Start
- 2024-07-29
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPG302 | Small molecule | 300 mg | Oral |